PT - JOURNAL ARTICLE AU - Qiling Su AU - Huiyan Feng AU - Tian Tian AU - Xiaoqian Liao AU - Yunhui Li AU - Xiaomao Li TI - Combination between Mifepristone and Methotrexate to Treat Ectopic Pregnancy: A Systematic Review Protocol AID - 10.1101/2021.09.26.21264155 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.26.21264155 4099 - http://medrxiv.org/content/early/2021/09/29/2021.09.26.21264155.short 4100 - http://medrxiv.org/content/early/2021/09/29/2021.09.26.21264155.full AB - Background In recent years, the morbidity of ectopic pregnancy and the proportion of young and childless patients have increased year by year, which makes it important to early diagnose EP, effectively save patients’ lives and furthest preserve their fertility. Methotrexate and mifepristone are most widely used in conservative treatments, however, there is no accurate conclusion about which therapy is better. Therefore, the aims in this meta-analysis are, on the one hand, to systematically analyze the efficacy of mifepristone combined with methotrexate in the treatment of ectopic pregnancy through existing studies, and to draw scientific conclusions. On the other hand, to fill the gap of relevant analysis in China and abroad, to evaluate the advantages and disadvantages of inclusion trials and propose improvement measures and scientific designing schemes.Methods Six electronic databases will be searched, including PubMed, Embase, Cochrane Library, the China National Knowledge Infrastructure(CNKI), Chinese Science and Technology Periodical Database (VIP), and Wanfang Database (WF). Literature from October 2015 to October 2020 on randomized controlled trials will be searched, without any language or publication restriction. Search terms include mifepristone, methotrexate, ectopic pregnancy, and random (free word/synonym expansion). Included in a randomized controlled trial, the treatment group was treated with mifepristone combined with methotrexate, and the control group was treated with mifepristone alone. Revman 5.4 (provided by Cochrane) will be used to evaluate the quality of the literature, and the corresponding effect model will be selected to analyze the results. The cure rate will be the main outcome index, and the remaining outcome measures after literature inclusion will be the secondary outcome indexes.Result Only when we finish this meta-analysis can we get the result.Discussion The results of this study will provide reliable evidence for the efficacy of mifepristone combined with methotrexate therapy in the treatment of ectopic pregnancy.PROSPERO registration number CRD42021246757Strengths and limitations of this study This study will systematically analyse the efficacy of combination between mifepristone and methotrexate to treat ectopic pregnancy and comes to a scientific conclusion. This study will fill the gap of relevant analysis in China and abroad. This study will evaluate the advantages and disadvantages of inclusion trials. This study will find out the reasons why most of the research results are not reliable enough, and propose measures for and scientific designing schemes.The quality of the trials may be generally low.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A Systematic Review Protocol is not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all data from this study are available.CIconfidence IntervalORdods ratioRCTsrandomized controlled trialsEPectopic pregnancy